The hedgehog pathway is a major regulator of embryonic development, and mutations that decrease its activity are known to be associated with severe defects in nervous system development. Recent evidence suggests hedgehog continues to function in adult tissue, normal as well as diseased, by regulating both cell proliferation and the production of growth and angiogenic factors. In the adult nervous system, this dual ability is especially important in regulating the behavior of neural stem and progenitor cells. This review summarizes information connecting hedgehog signaling and neural diseases, including neurodegenerative disorders and brain tumors, particularly medulloblastoma. We also describe the discovery and utility of small molecule agonists and antagonists of this pathway and their potential as novel types of therapeutics.
INTRODUCTION
The hedgehog (Hh) pathway is one of a small collection of pathways that control the numbers and types of cells formed during development in species ranging from Drosophila to humans. Whereas the most well-known Hh-pathway ligand sonic hedgehog (Shh) has been shown, in ever-expanding ways, to participate in central nervous system (CNS) development, another ligand, desert hedgehog (Dhh) , is essential for the proper formation of the peripheral nervous system (PNS). The purpose of this review is to highlight recent information about the ways in which the Hh pathway is involved in degenerative neural disorders and cancer. We also discuss therapeutic prospects for Hh agonists and antagonists.
Hedgehog Signaling Pathway
Although the three known mammalian Hh ligands [Indian hedgehog (Ihh) being the third] are expressed at different times and locations during development, they all seem to bind to the same receptors and regulate the same signaling pathway (reviewed in McMahon et al. 2003) . The ligands themselves are approximately 20 kD in molecular weight and are unique in having the N-and C-terminal amino acids both lipid modified (by palmitoyl and cholesterol addition, respectively), resulting in secreted proteins that are not freely diffusible. The main Hh receptor is the 12-transmembrane transporter-like protein patched-1 (Ptc1).
There are other Hh ligand-binding proteins present either on cells that synthesize the Hh ligand [e.g., dispatched (Burke et al. 1999) ] or on cells that respond to the ligand [e.g., patched-2 and hedgehoginteracting protein (Chuang & McMahon 1999 , Smyth et al. 1999 ]. In the off (nonliganded) state, Ptc inhibits the activity of another membrane protein, the 7-transmembrane, G protein-coupled receptor (GPCR)-like receptor smoothened (Smo), although exactly how this happens is not understood. In unstimulated cells, Ptc is located, at least in part, in the plasma membrane, with Smo being primarily intracellular. Following Hh binding, Ptc is internalized and degraded, while Smo translocates to the membrane, possibly after being phosphorylated (Denef et al. 2000) . This triggers a cascade of somewhat less-well-delineated events, the end result generally being an increase in levels of the transcription factor Gli1. Ultimately, there must be increased or decreased expression of sets of genes that control, in a context-dependent way, proliferation and differentiation. Interestingly, Ptc1 is a transcriptional target of Hh signaling, and its upregulation serves to dampen the degree of Hh signaling over time. Various aspects of the Hh pathway have been discussed in detail elsewhere .
Hedgehog Ligands and Neural Development
The participation of the Hh pathway in motor neuron differentiation in the developing spinal cord has been studied in most detail (Tanabe & Jessell 1996 , Briscoe & Ericson 2001 . In this case, Shh is made first by the notochord and secondarily by cells in the floorplate. Hh signaling has a dose-dependent 
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Parkinson's disease mechanism of action critical for its developmental functions because it is distributed in concentration gradients. Several features contribute to gradient formation across the embryonic spinal cord, including the hydrophobic nature of Hh protein, its ability to bind receptors on cells that produce as well as respond to Hh, and its association with extracellular matrix proteins. Taken together, these features enable Hh to act as a classical morphogen that promotes motor neuron formation by regulating the expression of families of transcription factors in cells along the ventral-to-dorsal axis. The dependence of motor neuron formation on Hh activity is not unique. Other cells of ventral origin (such as nigral dopaminergic neurons, striatal projection neurons, basal forebrain cholinergic neurons, and oligodendrocyte progenitor cells) are induced, at least in part, by Shh. Much of the original interest in a potential role for Hh in treating neurodegenerative disease was based on its participation in controlling the number of many of the types of neurons that degenerate during the course of various neurological disorders [e.g., dopaminergic neurons in Parkinson's disease (PD) (Ye et al. 1998) ]. Dhh also plays a role in nervous system formation, but its function is restricted to PNS development. Dhh is secreted by Schwann cells, but Ptc1 is present only on perineurial cells that make up the nerve sheath. Mice lacking Dhh form abnormal peripheral nerves with a discontinuous nerve sheath, a leaky blood-nerve barrier, low rates of action potential conduction, and resulting behavioral changes (Parmantier et al. 1999) . Presumably, the effects of Dhh are indirect, in that the ligand binds to its receptors on perineurial cells that secrete growth, neurotrophic, and angiogenic factors that cooperate to ensure appropriate nerve development and function.
Hh ligands also play a significant role in regulating proliferation as well as differentiation. Ihh is a mitogen for chondrocytes (Long et al. 2001) , whereas Shh is mitogenic for several cell populations, including (Palma et al. 2005) . That Hh ligands can, at times, regulate both proliferation and differentiation is central to appreciating their importance in embryonic development and to considering the various ways in which this developmental pathway can be usurped in adult diseases. Although Hh signaling is clearly necessary for the generation of neural and glial cell types, there is much less evidence that it can promote cell survival. Recombinant Hh protein introduced into developing chick embryos, in a standard test for neurotrophic factor-like activity, failed to decrease the number of motor neurons undergoing programmed cell death (Oppenheim et al. 1999) . However, there have been a small number of reports indicating that Hh signaling can decrease the death of cultured dopaminergic neurons after either trophic factor withdrawal or the addition of 1-methyl-4-phenyl-1,2,3, 6-tetraydropyridine (MPTP) (see below).
The Hedgehog Pathway and Developmental Disorders
The Hh gene was originally discovered in a Drosophila mutagenesis screen, and the profound role of the Hh family in mouse development was discovered by analyzing the phenotype of mice deficient for Hh ligands, or various components of the Hh signaling pathway. Numerous abnormalities are seen in these mice, ranging from embryonic lethality with severe nervous system deficits resembling the human birth defect holoprosencephaly in the case of Shh (Chiang et al. 1996) to dramatically shortened limbs and late prenatal/early postnatal death in the case of Ihh (St-Jacques et al. 1999) . Somewhat equivalent observations have been made in developing chick embryos and fetal sheep. Studies in both species-the former in ovo (Cooper et al. 1998) , the latter in the field (Binns et al. 1963 )-were carried out using natural product Hh inhibitors, such as the teratogens jervine and cyclopamine extracted from corn lilies. Treatment of pregnant animals at an early gestation period results in severe nervous system defects in their offspring that bear a strong resemblance to holoprosencephaly, with associated cyclopia (fusion of developing eyes at the midline). For some time, it was not clear how these compounds were acting. The jervinoids are sterols, resembling cholesterol in chemical structure. Because Hh proteins are covalently linked to cholesterol moieties, and because disrupted cholesterol metabolism leads to similar aberrant neural phenotypes, it was suggested that the compounds act by blocking the addition of cholesterol to Hh. However, this turned out not to be the case; in fact the compounds were later shown to act by binding to Smo and inhibiting Hh signaling (Chen et al. 2002 , Frank-Kamenetsky et al. 2002 .
As a result of the somewhat unusual nature of the Hh signaling pathway, with the receptor Ptc1 serving to actively inhibit the pathway in the absence of Hh ligand, increased signaling ensues when levels of functional Ptc1 decrease. Constitutively active forms of Smo (which, as for many GPCRs, are known to exist) also produce enhanced signaling in the absence of ligand. Such modifications also lead to a significant disruption of normal development and, in older organisms, promote the formation of certain cancers, as is discussed below.
Recently, Thibert et al. (2003) suggested that, at least during avian neural development, Ptc1, in its unbound state and independent of the canonical Hh signaling pathway, can actively stimulate apoptosis, thereby becoming a member of the dependence class of receptors. These results have not been replicated, and this mechanism is not known to play a role in any adult tissue or disease. Other recent experiments suggest the possibility that the Hh pathway may be able to regulate some aspects of neuronal behavior such as axonal growth, ANRV278-NE29-19 ARI 16 March 2006 16:6 rapidly and without changes in gene transcription (Trousse et al. 2001 , Charron et al. 2003 , Kolpak et al. 2005 . Whether this alternative means of signaling can explain any of the effects of Hh in neural disease models is discussed below.
Hedgehog is Important in Humans as Well
Not only are there developmental defects in animals with diminished Hh signaling, but similar alterations-holoprosencephaly with varying penetrance up to and including cyclopia-are also observed in human fetuses with Shh mutations (Roessler et al. 1996) . Furthermore, peripheral nerve developmental abnormalities with consequent neuropathies, somewhat similar to those in Dhhdeficient mice, are seen in a small number of people with Dhh mutations (Umehara et al. 2000) . Confirmatory evidence for the involvement of Hh signaling in normal human development also comes from observations made in individuals with nevoid basal cell carcinoma syndrome (Gorlin syndrome), of which there are at least 5000 cases in the United States. Gorlin syndrome patients show a preponderance of basal cell carcinomas (BCCs), with new tumors forming throughout life. These patients are also predisposed to other tumors, most notably medulloblastoma. Moreover, they have an increased incidence of meningioma, ovarian sarcomas and fibromas, and they exhibit skeletal abnormalities of various types, as well as radiation hypersensitivity (Gorlin 1987) . The major cause of this syndrome is heterozygosity of the PTCH1 locus (Hahn et al. 1996 , Johnson et al. 1996 . Decreasing PTCH1 activity leads to constitutive activation of the Hh pathway in the absence of Hh ligand binding. In short, these results confirm that normal Hh signaling is important in the regulation of proper tissue formation in species ranging from Drosophila to humans, as might be expected with the high degree of conservation of Hh and the components of its signaling pathway. Therefore, the therapeutic potential of regulating this pathway has been unclear. Events in the past few years have now supported a role for Hh signaling in adult biology and provided a foundation for the idea that modulators of this pathway-both antagonists and agonists-may have significant potential for treating different cancers and neurodegenerative diseases. This is no surprise given that the Hh pathway can directly control both entry into the cell cycle and cell differentiation in many different types of cells, at least during development. A major advance was made, following recognition of the link between PTCH1 and Gorlin syndrome, that the Hh pathway is upregulated in a high percentage of sporadically occurring BCCs , Dahmane et al. 1997 ; see also Oro et al. 1997) . The most frequent cause is mutational inactivation of PTCH1 (leading to activation of Hh signaling), but activating mutations of SMOH and loss of function of suppressor of fused (SUFU), another component of the Hh pathway, have also been seen (Reifenberger et al. 2005 (Lee et al. 2003) , with heterozygous loss of PTCH1 representing the most common known lesion (Fogarty et al. 2005) . However, to date, no other cancers have been identified in which these mutations occur with a significant frequency. Another way in which Hh ligands might be involved in regulating tumor growth was suggested by studies indicating that one or more Hh ligands may be synthesized by human tumor cells in relatively large amounts compared with normal adult cells. Tumor cellderived Hh may then activate signaling in other tumor cells, stimulating growth directly (i.e., an autocrine loop). Evidence is mounting that this autocrine effect is characteristic of numerous types of cancers, ranging from small-cell lung to pancreatic and prostate cancers , Thayer et al. 2003 , Watkins et al. 2003 , Karhadkar et al. 2004 , Sanchez et al. 2004 . In many of these cases, Hh antagonists seem to decrease the rate of tumor cell proliferation in vitro and in mouse xenograft models.
Another general observation has been that the normally quiescent Hh signaling pathway can be reactivated after tissue damage in the adult. For example, this has been seen in crushed sciatic nerve in which Schwann cell production of Dhh mRNA (and of Shh mRNA) increases enormously, yielding a large Hh response in nearby perineurial cells, which then increase their production of growth, neurotrophic, and angiogenic factors. Making hind limbs ischemic also upregulates production of Shh, ultimately leading to enhanced stromal cell production of angiogenic and other growth factors (Pola et al. 2001 (Pola et al. , 2003 . In both cases, application of an anti-Hh antibody slowed recovery from damage, and treatment with additional Shh protein stimulated recovery (Berg et al. 2000 , Pepinsky et al. 2002 . The ability of the Hh pathway to regulate growth factor production may account for some of its effectiveness in different models of neurodegenerative disease, as discussed below. However, this ability, in the context of a growing tumor producing high levels of Hh ligand, might further contribute to tumor growth (i.e., a paracrine effect), even beyond what is seen with the direct effects on tumor cell proliferation.
Identification of Small Molecule Hedgehog Antagonists
Once it became reasonably clear that the Hh pathway could be involved in adult disease, with BCC and medulloblastoma being the first ones recognized, attempts were made to identify small molecule Hh antagonists. Treating cancers caused by inactivating PTCH1 or activating SMOH mutations obviously would require small molecule inhibitors of Hh signaling acting at or below the level of SMOH. A cell-based reporter gene assay, in which a multimerized regulatory sequence from the Ptc promoter was used to control the expression of luciferase, was employed to screen a small molecule library. This led to the identification of numerous classes of Hh antagonists shown to block the effects of Hh ligands in different assays (Figure 1) , including motor neuron induction in developing spinal cord explants (Williams et al. 2003) . Two series of antagonists were optimized by focused medicinal chemistry; both were shown to bind directly to human smoothened (SMO). These antagonists were shown to be free of inhibitory activity when tested against other developmentally regulated pathways. Most important was the lack of inhibition of the Wnt pathway-because Wnt receptors, the Frizzleds, are the most highly related class of molecules to SMO. Furthermore, the antagonists were shown to be free of inhibitory activity on a variety of unrelated GPCRs (because SMO is a GPCR-like receptor). The first class of these Hh antagonists has now entered a phase I clinical trial as a topical treatment for BCC. The potential use of these antagonists in treating certain types of brain tumor is discussed below.
Identification of Small Molecule Hedgehog Agonists
Early on, it seemed obvious that developing a drug that acts by stimulating Hh signaling in the CNS would require the use of small molecule agonists that were blood-brain barrier permeant. Later, it also became clear that having such small molecules could actually facilitate the study of the participation of Hh in adult CNS function because they have provided a convenient way of activating Hh signaling in adult experimental organisms at any time.
It was never anticipated that small molecules that acted as pseudoligands for PTCH could be identified because it seemed improbable that small molecules that bind sufficiently well to the binding pocket used by endogenous Hh ligands could be discovered. Once assays were configured to detect Hh antagonists, they were also employed to see if small molecule agonist "hits" could be obtained. A class of biaryl agonists was identified and optimized, after a significant medicinal chemistry effort, for potency, oral bioavailability, and CNS penetration (Figure 1 ). The end result was a large number of structurally related compounds with subnM EC 50 in cell-culture assays (Frank-Kamenetsky et al. 2002) . These compounds are more potent than the actual protein ligands, and they have proven effective in activating the Hh pathway in various standard Hh assays carried out in vitro and on developing mice. For example, they can regulate, in a concentrationdependent fashion, the appearance of particular types of neural progenitors in developing spinal cord explants. In fact, Hh agonists act essentially as morphogens under appropriate circumstances in that, at low concentrations, they suppress the expression of dorsal spinal cord markers, whereas at higher concentrations, they increase the levels of ventral markers. After oral dosing of pregnant mice with the agonist, embryonic mouse development is substantially affected with a large increase seen, for example, in the number of Hh-responsive spinal cord progenitors. Different types of studies, ranging from genetic and pharmacological epistasis experiments to direct binding assays, demonstrated these agonists bypass Ptc and bind directly to Smo. In fact, this agonist class and the two small molecule antagonist classes described above, Wichterle et al. (2002) showed that a combination of retinoic acid and the Hh agonist could be used in combination to efficiently generate motor neurons from mouse embryonic stem cells.
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HEDGEHOG PATHWAY AND MEDULLOBLASTOMA
Overview
Medulloblastoma is the most common malignant brain tumor in children, with approximately 500 new cases diagnosed yearly in the United States. It is included in a group of morphologically and genetically diverse tumors, called primitive neuroectodermal tumors, a term frequently used to describe embryonal tumors. They arise in the cerebellum, most likely from GNP cells residing in the external germinal layer (EGL) of the developing cerebellum. They have a tendency to metastasize, most often within the CNS; however, some patients develop metastases to the bone, bone marrow, lymph nodes, liver, or lung. Medulloblastomas can be subdivided into five histologically distinct groups: the classic, desmoplastic, and large-cell anaplastic variants being most common and the melanotic and medullomyoblastoma types being exceedingly rare.
Medulloblastoma Genetics
The existence of distinct subtypes of medulloblastoma suggests this is a heterogeneous disease, and, indeed, there are many different genetic factors that influence medulloblastoma initiation, progression, and morphological appearance. The most common genetic abnormality linked to medulloblastoma, and usually associated with the largecell anaplastic variant, is loss or mutation of chromosome 17. Approximately 40%-60% of sporadic medulloblastomas show loss of heterozygosity of 17p (for reviews of chromosomal abnormalities in medulloblastoma, see Goussia et al. 2000 , Ellison 2002 , Gilbertson 2002 ). Significant insights into the causes of tumorigenesis have come from the identification of specific mutations linked to inherited syndromes associated with higher incidences of medulloblastoma. These include Li-Fraumeni syndrome, resulting from p53 gene inactivation (Malkin et al. 1990) , and Gorlin syndrome, linked to mutation in the PTCH1 gene (Hahn et al. 1996 , Johnson et al. 1996 . Since then, many studies have investigated PTCH1 status in medulloblastoma. It was found that 10%-20% of sporadic tumors harbor mutations in this gene (Pietsch et al. 1997 , Raffel et al. 1997 , Wolter et al. 1997 , Xie et al. 1997 , Zurawel et al. 2000a ), indicating lesions in Hh/PTCH1 signaling may contribute to the etiology of medulloblastoma. These data also explained the connection between LOH at 9q22.3-q32 and medulloblastoma, as this is linked to loss of the PTCH1 allele. Interestingly, this chromosomal abnormality is associated with the preservation of the remaining wild-type allele (Vorechovsky et al. 1997) , indicating heterozygosity at the PTCH1 locus is sufficient to promote medulloblastoma formation. PTCH1 mutations are not the only genetic lesions associated with disrupted Shh signaling in medulloblastoma; activating mutations of SMOH have been detected in up to 5% of sporadic medulloblastomas (Reifenberger et al. 1998) , and in one study, germline and somatic mutations in SUFU were found in 9% of children with medulloblastoma . To date, the desmoplastic subtype of the disease is proportionally more common among medulloblastomas with mutations in Hh-pathway components, including Gorlin syndrome tumors, sporadic medulloblastomas with mutations in PTCH1, SUFU, and SMOH genes, as well ANRV278-NE29-19 ARI 16 March 2006 16:6 as ones with chromosome 9q22.3 deletions (Schofield et al. 1995 , Nicholson et al. 1999 , Pietsch et al. 1997 , Pomeroy et al. 2002 .
Medulloblastoma Caused by Disruption of the Hedgehog Pathway
The first definitive proof that disruption in the Hh pathway can cause medulloblastoma came from the analysis of mice in which one copy of the Ptc1 gene was deleted (Goodrich et al. 1997 , Hahn et al. 1998 . Homozygous Ptc1 −/− mice are not viable-embryos die at 9.5 days of gestation with severe defects in the developing nervous and cardiovascular systems. The heterozygous mice have features of Gorlin syndrome, including increased body size, a low incidence of polydactyly, and cerebellar tumors that resemble human medulloblastoma.
There have been contradictory reports about whether the loss of the remaining wildtype Ptc1 allele is required for tumorigenesis. Several studies indicate that the wild-type allele continues to be expressed at low levels in primary mouse tumors. This has been shown by northern blot analysis of total RNA prepared from tumors arising in Ptc1 +/− mice (Wetmore et al. 2000) , as well as the sequencing of Ptc1 cDNA isolated from tumors and in situ hybridization on tumor sections (Zurawel et al. 2000b ). An additional study using in situ hybridization and real-time polymerase chain reaction (PCR) analysis also detected the expression of wild-type Ptc1 in tumors (Romer et al. 2004) . One study did suggest the wild-type Ptc1 allele might be silenced in tumors through DNA methylation (Berman et al. 2002) ; however, this conclusion was based on studying allograft-derived cell lines and should be evaluated further using tumor-derived cells, as the Hh pathway has been shown to undergo silencing when primary tumor cells are cultured in vitro (Romer et al. 2004) , and methylation could be one mechanism of this inactivation. In another study, the preneoplastic tumor cells in Ptc1 +/− mice were shown to lose expression of the wild-type Ptc1 allele (Oliver et al. 2005) . In this study, real-time PCR analysis was used to assay expression of Ptc1, in the absence of contaminating nontumor cells. This suggests that loss of Ptc1 expression is an early event in tumorigenesis, perhaps required for tumor progression. Even when low levels of Ptc1 are detected, the pathway is defective as the increased levels of Gli1 in these tumors should have elevated Ptc1 expression if the well-known negative feedback loop was functional. It is possible that the discrepancies reported in Ptc1 status among the various studies stem from differences in cell handling in the various in vivo and in vitro systems.
Medulloblastoma Formation: Mechanism of Action
Appropriate activity of the Shh pathway is required for normal development of the cerebellum, whereas abberant activity of this pathway can lead to the formation of medulloblastoma. A causal link between the Shh pathway and medulloblastoma was originally inferred from the etiology of Gorlin syndrome, in which a mutated Ptc1 allele predisposes individuals to developing medulloblastoma. This link was later demonstrated in Ptc1-mutant mice. However, the mechanistic relationship between deregulation of the Shh pathway and meduloblastoma formation is not fully deciphered.
Disruption of cell cycle in medulloblastoma. How does the loss of one allele of Ptc1 and/or increased expression of Gli1, either through Ptc1 loss or mutations in other upstream components of the pathway, contribute to tumorigenesis? The mechanism by which deregulation of the Hh signaling leads to medulloblastoma formation is still unclear, but many studies point to a close connection between activated Hh signaling and impaired cell-cycle control. In part, this was inferred through analysis of gene expression in medulloblastoma. Tumors with mutations in Hhpathway components express high levels of Gli1, as well as N-Myc and C-Myc, CyclinD1 and CyclinD2 (Pomeroy et al. 2002 , Lee et al. 2003 .
The genes highly expressed in medulloblastoma are often also present in the developing cerebellum (Lee et al. 2003) , suggesting medulloblastoma cells may be similar to immature GNP cells and that studying mechanisms involved in proliferation of GNP cells may provide insight into the mechanisms involved in tumorigenesis. In normal cerebellar development, Hh signaling is necessary for the proliferation of GNP cells in the EGL. Shh is released from Purkinje neurons and binds to Ptc1 on GNP cells. This has been shown in several different in vitro and in vivo studies (reviewed in Wechsler-Reya & Scott 2001). This major mitogenic role of Shh has been linked to cell-cycle control through experiments showing that Shh could induce expression of the G1 cyclin genes (Kenney & Rowitch 2000) . The addition of Shh to isolated GNP cells resulted in substantial elevation of cyclin D1, D2, and E mRNA levels. Interestingly, this increase required protein synthesis, implying that production of intermediate proteins was needed to upregulate expression of these cyclin genes. The elevation of d-type cyclin levels was linked to the activity of the Rb pathway as measured by increased Rb phosphorylation, possibly indicating that sustained proliferation of Shh-treated GNP cells involves the release of inhibition of E2F transcription factors by Rb, permitting S-phase entry.
As well as inducing sustained proliferation through d-type cyclin genes, Shh stimulation has also been shown to hamper exit from cell cycle, in part through blocking cell-cycle arrest induced by the cyclin-dependent kinase inhibitor p21 CIP1 (Fan & Khavari 1999) . This is most probably a consequence of an Shh-induced increase in activity of the cyclindependent kinases CDK2 and CDK4. This is important as during normal cerebellar development, immature GCPs must exit the cell cycle prior to migrating out of the EGL and undergoing terminal differentiation.
Another connection between the disruption in cell cycle and Hh-dependent medulloblastoma comes from the finding that the Bmi1 protein, a member of the polycomb group of transcription factors, is overexpressed in the subset of human medulloblastomas that express high levels of Hh-target genes. Bmi1 is expressed in the EGL of the developing cerebellum (Leung et al. 2004 ) and is essential for normal cerebellar development (van der Lugt et al. 1994 ). Its expression appears to be regulated by Hh signaling (Leung et al. 2004) . Bmi1 affects the cell cycle through its inhibition of the cyclin-dependent kinase inhibitor p16
Ink4a and the tumor suppressor p19
Arf . This can potentially lead to the repression of both p53 and Rb function, through p19
Arf and p16 Ink4a , respectively.
Control of growth factor production by hedgehog signaling. In other circumstances (e.g., following tissue damage) elevated Hh signaling is known to upregulate growth factor production. In fact, the levels of Igf2, a known mitogen for many cell types, are high in Ptc1 +/− tumors, such as rhabdomyosarcoma and, presumably, medulloblastoma. Furthermore, Igf2 activity appears necessary for the formation of both medulloblastoma and rhabdomyosarcoma in Ptc1 heterozygous mice (Hahn et al. 2000) . This suggests that Igf2 is one of the targets of the Hh pathway that confers an additional growth advantage to these types of tumor cells. Notch signaling may also be important for the formation of Shh-induced tumors (Hallahan et al. 2004) . Mice engineered to constitutively express an activated form of Smo have a high incidence of medulloblastoma, and both Shh and Notch target genes are highly expressed in these tumors. Additionally, pharmacological inhibition of Hh and Notch signaling, especially in concert, suppresses the growth of medulloblastoma cell lines and both mouse and human medulloblastoma cells (Hallahan et al. 2004) . Thus, Hh activation may not only directly regulate cell proliferation, but also may contribute to enhancing medulloblastoma 
The Therapeutic Potential of Hedgehog Pathway Inhibition in Medulloblastoma Current Therapy
Patients are diagnosed with medulloblastoma by the location of the tumors and their histopathological appearance. In the United States, currently employed therapy consists first of surgical resection (Ellison et al. 2003 , Gilbertson 2004 ). Adjuvant chemotherapy and radiation therapy follow the surgery, and the doses of radiation used are adjusted according to the patient's risk. Radiation treatment, especially in young children, has devastating and lasting effects on intellect and neuroendocrine function (Palmer et al. 2001 , Ris et al. 2001 , Freeman et al. 2002 , Gurney et al. 2003 . For this reason, children under the age of three are treated with chemotherapy alone, and, partly as a consequence, their prognosis is usually dismal. Further advances in medulloblastoma therapy will likely focus on developing novel therapies based on targeting the specific molecular defects found in medulloblastoma. The Shh pathway may be an appropriate molecular therapeutic target, at least for certain patients.
Experimental Models of Medulloblastoma
Testing targeted therapies offers new challenges. Most of the standard cytotoxic therapies are first tested using in vitro systemsrepetitively passaged cultured tumor-derived cell lines-or xenografts using immunocompromised animals into which cells, most of the time the same cultured tumor cells, are injected subcutaneously. The shortcomings of such preclinical models of cancer are beginning to be fully recognized (Romer & Curran 2005) , and their inability to predict clinical outcome has been apparent for some time. This is especially important for testing targeted therapies because this testing relies heavily on having models that maintain the molecular defects of the human disease being targeted. The cultured tumor cells often undergo selective growth pressures associated specifically with artificial in vitro culture conditions. This can lead to molecular changes in the cultured cells that, as a consequence, become increasingly different from their tumors of origin. Xenografts recapitulate neither the microenvironment nor the developmental time frame of human disease. For example, in many cultured medulloblastoma cell lines the activity of the Hh pathway is downregulated, with the resultant absence of expression of Hh target genes, and a lack of proliferative and molecular response to Shh stimulation (Romer et al. 2004 ).
Efficacy of Hedgehog Antagonists in Medulloblastoma Models
The inhibition of the Hh pathway has been investigated in several preclinical medulloblastoma models. Cyclopamine, for instance, has been tested both in vivo and in vitro. In one study Berman et al. (2002) treated cultured cell lines derived from allografts of medulloblastomas that arose spontaneously in Ptc1 +/− p53 −/− mice with cyclopamine, resulting in decreased cell numbers. When they injected cyclopamine into the flank of allograft-carrying mice, they noted a reduction in tumor cell proliferation, which produced a decrease in tumor volume. The therapeutic potential of Hh-pathway inhibitors was also tested in primary cultures of freshly resected human medulloblastomas. Cyclopamine treatment decreased PTCH1 expression and reduced tumor cell viability in seven out of seven samples used. This preliminary study is encouraging because it suggests Hh antagonists might be more broadly active than predicted from knowing the percent of tumors with Hh-pathway mutations, but needs further exploration.
In a more recent study Romer et al. (2004) standard cell culture and allograft systems by using Ptc1 +/− p53 −/− mice, which spontaneously develop medulloblastoma. They treated the mice with an Hh antagonist, HhAntag-691, identified in the assays described above. This treatment decreased tumor cell proliferation dramatically, increased tumor apoptosis, and, at the highest dose used, led to the complete elimination of tumors from the brains of treated animals (Figure 2) . These effects were associated with pathway suppression as shown by assaying the expression of endogenous Shh pathway target genes, including Gli1, by quantitative real-time PCR and in situ hybridization. However, the treatment did not affect Ptc1 expression, indicating that in tumors, Ptc1 transcription is not a target of Shh signaling and may have lost its normal role in the negative feedback loop that regulates the magnitude of Hh signaling.
Sanchez & Ruiz i Altaba (2005) obtained similar results with the Ptc1
+/− p53 −/− mice using cyclopamine to inhibit Hh signaling. These studies strongly suggest that the inhibition of the Shh pathway may be an effective targeted therapy for medulloblastoma.
Use of Hedgehog Inhibitors to Treat Genetically Diverse Medulloblastoma
Patients most likely to benefit from treatment with Hh antagonists are those with Gorlin syndrome and those with sporadic medulloblastoma in which the Hh pathway is activated by mutation. However, other patients may also be able to be treated by inhibiting Hh signaling, as over 30% of sporadic medulloblastomas express a high level of Hh target genes, including Gli1 (Lee et al. 2003) . This has also been suggested by studies comparing expression profiles of different mouse models of medulloblastoma. Mice that develop medulloblastoma on Lig4 (Tong et al. 2003) .
It is unclear how Gli1 is induced in these genetically different tumors. One example is the loss of the REN KCTD11 gene, which leads to upregulation of Gli1 in medulloblastoma. This gene localizes to chromosome 17p13.2, and, as mentioned above, allelic loss of 17p is the most frequent genetic defect in human medulloblastoma. Allelic deletion or reduced expression of REN KCTD11 gene has been detected in a subset of sporadic human medulloblastomas (Di Marcotullio et al. 2004) . Conversely, increased REN KCTD11 expression leads to decreased proliferation of medulloblastoma-derived cell lines in tissue culture and xenografts. This inhibitory action is perhaps related to REN KCTD11 suppression of Gli1 activity, possibly through inhibiting translocation of Gli1 to the nucleus (Di Marcotullio et al. 2004) . Taken together, these results suggest REN KCTD11 is a negative regulator of Shh signaling, and its loss may be one of the mechanisms in which sustained Shh activity can be achieved in medulloblastoma. Thus the Hh pathway may have a more general role in the induction of medulloblastoma, and Hh inhibitors may have therapeutic potential in a substantial subset of this serious childhood brain tumor. This is consistent with Berman et al.'s (2002) results mentioned above.
THE HEDGEHOG PATHWAY IN OTHER TYPES OF BRAIN TUMORS
It appears that medulloblastomas in which the Shh pathway is activated are derived from cerebellar GNP cells that are normally regulated by Hh signaling. When the Hh pathway is inappropriately maintained in this cell population, GNP cells fail to exit the cell cycle and continue to proliferate without control, leading to tumor formation. It can be said, therefore, that medulloblastoma results from an aberration of normal development, involving hyperactivation of the Hh pathway and overproliferation of progenitor cells normally dependent on Hh signaling for their growth.
Extrapolation of this paradigm suggests deregulation of the Hh pathway may be involved in the formation of tumors derived from other stem/progenitor cells that depend on Hh signaling to proliferate during normal development. If tumors arise from such stem/progenitor cells that accumulate mutations allowing for their continual and uncontrolled proliferation, then other Glipositive progenitors possibly are capable of being transformed and giving rise to different CNS tumors. In fact, Gli1 was first described as a gene amplified in human glioma (Kinzler et al. 1987) . Additional studies have failed to confirm the link between glioma and the Hh pathway. However, these studies may have been somewhat misleading, focusing more on the amplification of the Gli1 gene rather than on inappropriate Gli1 expression.
More recently, Dahmane et al. (2001) showed that several CNS tumors of different origin express high levels of GLI1, indicating that activated Hh signaling might be important for their genesis or maintenance. Astrocytoma, oligodendroglioma, glioblastoma multiforme, and primitive neuroectodermal tumors have all been found to express targets of Hh signaling, including GLI1. In this study, Dahmane et al. tested 22 independent tumors using either real-time PCR alone or both real-time PCR and in situ hybridization, and all of the tumors consistently expressed GLI1 with the majority also expressing other components of the Hh pathway, including SHH, PTCH1, and GLI2. As controls, they tested an ependymoma and a hemangioma, and neither expressed GLI1.
These data raise the possibility that Glipositive precursors from different locations of the dorsal brain can contribute to the formation of CNS tumors. To test this idea, selected glioma-and glioblastoma-derived cell lines were cultured in the presence of cyclopamine.
Three out of seven lines tested responded to the treatment with decreased proliferation, as did one of three primary cortical glioma cells. Therefore, there are perhaps brain tumors other than medulloblastoma for which Hh antagonists may constitute an effective therapy. However, further work is needed to explore this idea more completely, as well as to identify markers that may characterize those CNS tumors most reliant on Hh-pathway activity.
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HEDGEHOG SIGNALING IN NEURODEGENERATIVE DISEASE Overview
The importance of the Hh pathway in embryonic neural development has been thoroughly documented (Tanabe & Jessell 1996 , Briscoe & Ericson 2001 , but the role of Hh signaling in the adult brain is less well understood.
In the adult rodent CNS and PNS, Hh ligands and their receptors, Ptc and Smo, are present although the magnitude of Hh signaling seems to be lower and more restricted spatially (Traiffort et al. 1998 (Traiffort et al. , 1999 Machold et al. 2003; Coulombe et al. 2004 ). However, the potential for Hh ligands to function still exists. For example, viral overexpression of Shh is able to stimulate the proliferation of neural stem cells in the hippocampus (Lai et al. 2003) . In addition, as mentioned above, tissue damage is able to upregulate the production of Hh ligands and activate Hh signaling as part of the tissue-repair process (Pola et al. 2001) . These observations prompted an exploration of the potential for stimulating Hh signaling to promote functional recovery in models of neurodegenerative disease. Generally, experiments have provided convincing support for neuroprotective and regenerative activities following sufficient activation of the Hh pathway in disorders ranging from PD to stroke to peripheral neuropathy.
Hedgehog Pathway in Parkinson's Disease
PD is a progressive neurological disorder characterized by the loss of dopaminergic neurons in the substantia nigra. Shh is known to be involved in the differentiation of those very dopaminergic neurons during embryonic development (Hynes et al. 1995) . There are also data suggesting Shh can promote the survival, at least in vitro, of fetal dopaminergic neurons once they have differentiated and can protect them from the toxic effects of N-methyl-4-phenylpyridinium (Miao et al. 1997 ). In addition, neural progenitor cells isolated from the subventricular zone (SVZ) of neonatal mice secrete Shh and have been shown to protect developing dopaminergic cells in vitro (Rafuse et al. 2005) . Unilateral 6-hydroxydopmaine (6-OHDA) lesions are commonly used as a rat model of PD. When injected unilaterally into the striatum, 6-OHDA is taken up into the terminals of dopaminergic neurons resulting in a decrease in the dopaminergic innervation of the striatum (as judged by the density of tyrosine hydroxylase positive fibers) and a loss of dopaminergic neurons in the substantia nigra. Administration of dopamine agonists (such as apomorphine) or agents that block dopamine reuptake (such as amphetamine) results in easily quantified rotational behavior that reflects the degree of asymmetry (and, thereby, the loss of striatal innervation). In this model system, injections of Shh protein directly into the affected striatum significantly reduced apomorphine-induced rotation behavior (Tsuboi & Shults 2002) . Recently, Shh-secreting neural progenitor cells were further shown to improve motor behavior when transplanted into 6-OHDAtreated rats (Rafuse et al. 2005) . Finally, systemic administration of the neurotoxin MPTP in marmosets results in reduced dopamine levels and impaired motor function similar to that seen in PD patients. Administration of Shh unilaterally into the substantia nigra of MPTP-marmosets partially reversed both the behavioral and neural effects in a dose-dependent manner (Dass et al. 2002) . These data indicate that Shh can be neuroprotective in animal models of PD. ANRV278-NE29-19 ARI 16 March 2006 16:6 Positive behavioral effects in rodent PD models with Shh treatment are not always associated with the sparing of dopaminergic terminals in the striatum or cell bodies in the substantia nigra. By contrast, glial-derived neurotrophic factor, when injected into the brain of 6-OHDA-lesioned rats, normalized turning behavior while consistently attenuating the loss of dopamine resulting from the lesion (Bjorklund et al. 1997 ). This raises the possibility that Hh-pathway activators may act via an entirely different mechanism. One such mechanism is based on the finding that, in vitro, Shh protein can rapidly, within minutes of application, reduce electrical transmission of cells in the adult subthalamic nucleus (STN) (Bezard et al. 2003) . PD symptoms are in part induced by overactivity of the STN cells, and surgical or electrical inactivation of these cells generally provides symptomatic relief for PD patients. In 6-OHDA-lesioned rats, there is a reduction in the level of Shh in the globus pallidus, the neurons that project to the STN, and hyperactivity of the STN cells (Bezard et al. 2003) . Therefore, normalization of Shh signaling via protein or agonist treatment might improve 6-OHDA-induced rotational behavior by reducing hyperactivity of STN neurons.
Hedgehog Pathway and Peripheral Neuropathy
Whereas Shh is primarily important for CNS development, the morphogenic effects of Dhh are seen in the PNS. Treatment with Hh protein has been shown to be protective and/or enhance regeneration in PNS injury models. In a mouse-nerve-crush model, Shh and Dhh mRNA levels were dramatically elevated following injury, and Hh signaling increased significantly. Treating mice with anti-Hh monoclonal antibodies increased recovery time, whereas periodic injection with recombinant Hh protein modified to have prolonged serum half-life accelerated recovery (Pepinsky et al. 2002) .
Diabetes mellitus is a chronic metabolic disease accompanied, in a significant number of cases, by peripheral neuropathies (pain and loss of sensation as the main symptoms) and, ultimately, by nerve-fiber degeneration.
In the rat streptozotocin model of diabetes, pancreatic beta cells are killed, leading to hyperglycemia. Over time, there is a reduction in the rate of action potential propagation in both motor and large sensory nerve fibers. In this model, a decreased level of Dhh mRNA in peripheral nerves associated with the development of diabetes was observed (Calcutt et al. 2003) . Treatment with exogenous recombinant Hh protein starting 5 weeks after the onset of diabetes and continued for an additional 5 weeks resulted in the complete restoration of nerve-conduction velocity to control, nondiabetic, levels (Calcutt et al. 2003) . Hh treatment also attenuated the diabetes-induced decrease in nerve growth factor expression and the reduction in the proportion of large fibers in the sciatic nerve. In a second study, Kusano et al. (2004) monitored sensory and motor conduction velocities for 12 weeks postinduction of diabetes by streptozotocin. Again, treatment with Hh protein after the onset of symptoms significantly improved nerve-conduction velocity in diabetic rats (Kusano et al. 2004) . In this experiment, there was also a marked improvement in nerve blood flow after treatment. Improved blood flow and accelerated recovery of function are also seen in ischemic hind limbs following treatment with Shh (Pola et al. 2001) . Blood flow in the nerve does decrease in diabetesin rodents and in humans-leaving the nerve ischemic and perhaps accounting, in part, for its decreased function. These data, taken together with the positive effects in the nervecrush model, indicate that Shh protein can have significant effects on nerve recovery from injury or disease. As mentioned above, the apparent mechanism of action underlying these effects is the ability of Hh to stimulate the production of neurotrophic and angiogenic factors in nerve perineurial cells. Frank-Kamenetsky et al. 2002) . Furthermore, these Hh agonists are active at low nanomolar concentrations and have good bioavailability. They have also been demonstrated to readily cross the blood-brain barrier and activate Hh signaling (as judged by an increase in Gli1 expression) in the CNS following systemic administration (Machold et al. 2003) .
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To determine if these small molecules are efficacious in animal models of disease, they were tested first under circumstances in which Shh protein had been effective. Similar tothat seen with intrastriatal Shh protein, treatment with agonist either by ventricular infusion or systemic administration significantly improved apomorphine-induced rotation behavior in the rat 6-OHDA model (Boucher et al. 2004) . Agonist treatment was only required during the first week after 6-OHDA to see behavioral effects that lasted up to 6 weeks postlesion.
It was also important to identify other neurological indications for which Hh agonist might be a useful therapeutic. In the United States, approximately 700,000 people each year suffer a stroke. Although many compounds have gone into clinical trial, efficacious treatment options are still unavailable for stroke patients. For those that survive, sensory, motor, and/or cognitive functions can be severely affected depending on the location of the infarct. Similar to that seen in other injury models, including nerve crush and hindlimb ischemia, Gli1 mRNA levels increased in the brains of mice following transient middle cerebral artery occlusion (tMCAO), a stroke model (Figure 3a) (Dellovade et al. 2002) . Therefore, it was hypothesized that, similar to other types of injury in which Hh-pathway genes are upregulated, exogenous Hh treatment might accelerate recovery of function. It also had been observed previously that recombinant Hh protein and Hh agonists were effective in limiting neuronal cell death after malonate treatment, another excitotoxicity model, often used to test potential therapeutics for Huntington's disease (Dellovade et al. 2002) .
To test this hypothesis, small molecule Hh agonists were used in rat and mouse models of focal ischemia. In both species, an intraluminal suture model of tMCAO in which occlusion is induced using a poly-lysine-coated suture via the internal carotid artery. In rats, the middle cerebral artery was occluded for 90 min, and rats were examined for changes in body weight and behavioral recovery 24 and 48 h post-stroke. Forty-eight hours postocclusion, rats were euthanized, and infarct size was measured in brain slices. Dosing with Hh agonist 6 h after the onset of occlusion reduced infarct volume by approximately 40%-50% in rats (Figure 3b) (Dellovade et al. 2004 ). Significant effects on infarct volume were seen in both the cortical and subcortical regions. In addition, a single dose of agonist also reduced weight loss and improved neurological behavior (Dellovade et al. 2004 ). In several series of studies, a single dose of Hh agonist administered up to at least 6 h post-tMCAO significantly decreased infarct volume in both rats and mice (Dellovade et al. 2002 (Dellovade et al. , 2004 .
Possible Mechanism of Action for Neuroprotective Effects of Hedgehog Agonists
That Hh-pathway activators might promote recovery of function after stroke was ANRV278-NE29-19 ARI 16 March 2006 16:6 consistent with that seen in earlier studies of nerve crush, diabetic neuropathy, and hindlimb ischemia. It was somewhat unexpected that Hh agonists would be neuroprotective in stroke (and in malonate excitotoxicity) models, and the mechanism of neuroprotection is not completely understood. One possibility is that Hh directly activates neuronal survival pathways (such as that regulated by PI-3-kinase). Currently, there are no direct supporting data, but Hh signaling does appear to stimulate this survival pathway in at least endothelial cells (Kanda et al. 2003) . Another possibility is that the Hh agonist directly regulates synaptic activity such that the excitotoxic effects initiated by ischemia are minimized. Again, there is no experimental support for this hypothesis. However, as discussed above, there has been at least one suggestion that Hh can regulate synaptic transmission. Furthermore, as mentioned above, there are a few recent publications supporting the idea that Hh can have rapid effects on growth cones, at any rate. This possibly novel mechanism requires further exploration. Recent data showing the cells types that express the various Hh-pathway members in the adult brain might provide some clues toward mechanism. Evidence indicates that certain neuronal populations synthesize and secrete Shh, whereas astrocytes, and perhaps other types of glia, respond to secreted Shh, as demonstrated by increases in Gli1 and Ptc expression . Because astrocytes are known to respond to brain insult by the secretion of various neurotrophic factors, Hh agonists may act indirectly to mediate neuroprotection via changes in astrocyte gene expression. In support of this hypothesis, Shh has been shown to regulate expression of such factors in vitro. For example, Shh protein can induce brain-derived neurotrophic factor and insulin-like growth factor 1 expression in cultured fibroblasts (Allendoerfer et al. 2001) . Similarly, Shh can regulate the expression of cytokines involved in angiogenesis, such as vascular endothelial growth factor and angiopoietins from mesenchymal cells (Pola et al. 2001) . Finally, in diabetic rats, treatment with Shh protein increases nerve growth factor mRNA levels in the sciatic nerves (Calcutt et al. 2003) . 
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Effects of Hedgehog on Stem Cells
The Hh pathway regulates the expansion of precursor cells and their differentiation in several regions of the developing CNS, including the cerebellum and spinal cord. In all adult mammals, including humans, there are at least two brain regions where stem cells exist, the hippocampal dentate gyrus (DG) and the SVZ of the lateral ventricles. In both regions, new neurons are continuously born in normal animals, and a number of factors can influence this steady state. For example, neurogenesis is increased when animals are placed in an enhanced environment or are allowed to exercise (Kemperman et al. 1997 , Gould et al. 1999 , van Praag et al. 1999 . Conversely, stress hormones and anxiety/depression have been shown to decrease precursor cell proliferation in the DG, and treatment with antidepressants can reverse this effect (Gould et al. 1997 (Gould et al. , 1998 Malberg et al. 2000; Santarelli et al. 2003) . These data highlight the potential of the adult brain endogenous stem cell populations to enhance recovery and repair following brain injury or disease. Certainly, there has been a great deal of interest in identifying therapeutics that will increase neural stem cell proliferation, migration, neuronal differentiation, and incorporation into neuronal circuitry. Agents that can do this may constitute parts of therapeutic regimes for treating disorders ranging from stroke to PD and Alzheimer's disease to depression. Some recent data are supportive of this general idea. Arvidsson et al. (2002) found that, following tMCAO in rats, proliferation increased in the SVZ, and they noted the migration of the newly formed neurons to the area of damage in the striatum. However, several weeks after injury few of the new neurons had survived, suggesting the post-stroke environment did not support the incorporation of the new cells into the region of damage. Nakatomi et al. (2002) had generally similar findings in a rat model of global ischemia and further observed that ventricular infusion of known stem cell mitogens (βFGF and EGF) stimulated stem cell proliferation and culminated in an enhancement of the other processes as well, ultimately leading to the appearance of new neurons and to behavioral improvement. These data suggest exogenous therapies that enhance survival, as well as the proliferation and migration of neural progenitors, could facilitate the brain's own recovery mechanisms.
In both the SVZ and DG of adult rodents, Hh-pathway genes are expressed (Lai et al. 2003 , Palma et al. 2005 , and systemic dosing with Hh agonist increased Gli1 mRNA levels in both regions within 24 h postdosing (Machold et al. 2003) . In addition, precursor cell proliferation was significantly elevated in both the SVZ and DG following systemic dosing with Hh agonist as compared with vehicletreated controls. These data are in agreement with in vitro results demonstrating increased proliferation of both DG and SVZ precursor cells in response to Shh protein treatment (Lai et al. 2003 , Palma et al. 2005 . Finally, Palma et al. (2005) recently demonstrated that the administration of cyclopamine reduced both Gli1 mRNA levels and precursor cell proliferation in the SVZ, and prolonged treatment ultimately reduced the numbers of bromodeoxyuridine immunoreactive neurons in the olfactory bulb (Palma et al. 2005) . These data clearly demonstrate a vital role for Shh signaling in neurogenesis in the adult brain. Studies are underway to test whether activation of the Hh pathway is associated with long-term behavioral recovery via neurogenesis that may be enhanced by agonist treatment after stroke. If this were true, it would suggest that Hh-pathway agonists have the unique ability to both minimize cell death and lead to the appearance of new neurons after CNS damage.
CONCLUSIONS
The critical role played by the Hh pathway during embryonic development implies that it regulates essential biological processes. Therefore, its reappearance as a modulator ANRV278-NE29-19 ARI 16 March 2006 16:6 of adult disease is not entirely unexpected.
In the context of tumor growth, Hh signaling appears to act both directly and indirectly to stimulate and maintain the proliferation of tumor cells. In damaged neural tissue, it is neuroprotective and offers the possibility of regenerating damaged tissue. Drug-like Hh agonists and antagonists have been identified, and it will be exciting and challenging to assess their true therapeutic potential.
SUMMARY POINTS
1. Small molecule agonists and antagonists to the Hh pathway have been isolated and characterized for use as therapeutics for CNS disorders and cancer, respectively.
2. Activation of the Hh pathway is neuroprotective and regenerative in models of PD, stroke, and diabetic neuropathy.
3. Activation of the Hh pathway increases the proliferation and neuronal differentiation of endogenous precursor cells in the adult brain.
FUTURE DIRECTIONS
1. The effects of Hh agonist-induced mobilization of endogenous stem cells on repair and regeneration following CNS injury and disease should be explored. 
